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This best evidence topic was investigated according to a structured format. The question asked was:
should duplex ultrasound (DUS) scanning be a routine component of surveillance following infrainguinal
arterial bypass using vein conduit? We performed a systematic literature search and identified 4 studies
(3 randomised controlled trials and 1 meta-analysis) that provided the best evidence.
The highest quality study was a multi-centre randomised controlled trial (n ¼ 594). At 18 months
following surgery, it found no difference in patency rates, amputations, vascular mortality or mortality.
However it achieved just over half of anticipated recruitment and thus was underpowered. The
remaining two randomised controlled trials had smaller sample sizes and methodological weaknesses
and found conflicting results. Lundell et al. (n ¼ 106) found improved primary assisted and secondary
patency rates and fewer graft occlusions with a routine DUS policy. Ihlberg et al. (n ¼ 152) found no
difference in primary assisted patency or amputations although secondary patency was improved. A
meta-analysis of mostly observational data (n ¼ 6649) found fewer occlusions with routine DUS sur-
veillance and no effect on amputations or mortality.
Results are conflicting. The strongest evidence comes from the single high quality multi-centre trial. It
appears as though routine DUS surveillance does not yield benefits in patient important outcomes.
Further studies are needed.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
This best evidence topic was generated according to the struc-
ture outlined in International Journal of Surgery [1].y).
by Elsevier Ltd. All rights reserved2. Clinical scenario
A patient who had a femoropopliteal bypass using a long
saphenous vein conduit 6 weeks ago attends for routine follow-up
at a vascular surgery clinic. Clinical examination and ankle brachial
pressure index (ABPI) measurement are satisfactory. The vascular
surgery consultant advises that the patient should undergo regular
duplex ultrasound (DUS) as part of a surveillance program. You are
unsure about the quality of the evidence underlying this strategy
for vein grafts and you decide to assess the literature..
Table 1
Summary of best evidence papers.
Author, date
and country
Patient group Study type and level of
evidence





594 patients who underwent
femoropopliteal or femorocrural
vein bypass and had patent grafts at
30 days after surgery. 290 were
randomised to clinical follow-up
and 304 were randomised to
clinical follow-up with routine DUS.
Follow-up for both groups was at 6
weeks and at 3, 6, 9, 12, and 18
months after surgery. Patients in
both groups could undergo further
imaging and procedures as
necessary. Baseline characteristics
were similar and similar numbers
were lost to follow up. All patients
















cost and quality of life




assisted patency and secondary
patency rates at 18 months in
clinical versus DUS groups were
69% versus 67% (p ¼ 0.516), 76%
versus 76% (p ¼ 0.916) and 80%
versus 79% (p ¼ 0.663).
At 18 months 39/204 in the
clinical group versus 25/211 in
the DUS group had graft
stenoses detected.
46/290 clinical group patients
had a therapeutic intervention
within 18 months versus 66/
304 DUS group (p ¼ 0.07).
There were 21 amputations in
clinical group versus 21 in
duplex (HR 1.01; 95%CI 0.55
e1.86).
Vascular death occurred in 10
clinical group patients and 12
DUS patients (HR 1.21; 95%CI
0.52e2.81).
There were 31 cases of
mortality in clinical group
versus 26 in duplex group (HR
1.22; 95%CI 0.75e1.98).
Duplex group patients incurred
higher cost (mean difference
£495; 95%CI £183e£807). There
was no difference in quality of
life.
This was a large multicentre
trial that found no differences
resulting from surveillance
policies. Time to amputation,
time to vascular death and
quality of life were similar.
There was no significant
difference in requirements for
therapeutic interventions
between groups and patency
rates at 18months were similar.
Notably the trial achieved just
over half of anticipated
recruitment leaving it prone to








156 patients who underwent
primary femoropopliteal or
femorodistal bypass (vein or
synthetic graft). 77 patients were
randomised to “routine follow-up”
(clinical examination and ABPI) at 1,
12, 24 and 36 months following
surgery. 79 were randomised to
“intensive follow-up” (clinical
examination, ABPI and graft DUS) at
1, 3, 6, 9, 12, 15, 18, 24 and 36
months following surgery. There
were 56 patients with vein grafts in
the intensive group and 50 with
vein grafts in the routine group.
Baseline characteristics were











occlusions at 3 years
following surgery.
Regarding only those with vein
grafts, 3 year primary assisted
patency and secondary patency
rates in “routine” versus
“intensive” groups were 53%
versus 78% (p < 0.05) for
primary assisted patency and
56% versus 82% (p < 0.05) for
secondary patency.
During follow-up 4/50 grafts in
the “routine” group underwent
therapeutic intervention
compared to 12/56 in the
“intensive group” (p ¼ 0.062).
20/50 grafts in the “routine”
group occluded versus 11/56 in
the “intensive” group
(p ¼ 0.032).
This was a small single centre
trial and results at 3 years
favoured “intensive” follow-up.
Primary assisted and secondary




performed in the “intensive
group”. Notably this trial
compared “intensive” versus
“routine” surveillance rather
than routine DUS versus
selective imaging e the
increased number of follow-up
visits in the DUS group is a
source of bias. Furthermore, no
protocol is available and aspects
of methodology are unclear,
especially for randomisation
and treatment allocation. It is
unclear whether outcomes
were prespecified and there
was no sample size justification.
Ihlberg [6]
1998 Finland
Patients who underwent primary
infrainguinal arterial bypass using
vein conduit. 76 patients were
randomised to a follow-up schedule
comprising clinical examination
with ABPI measurement and 76
patients were randomised to a
group that additionally underwent
DUS at each visit. Follow-up visits
for both groupswere at 1, 3, 6, 9 and











salvage rates at one
year.
At one year, primary assisted
patency rates were 74% in the
clinical group and 65% in the
DUS group (p ¼ 0.21),
secondary patency rates were
84% and 71% respectively
(p ¼ 0.04) and limb salvage
rates were 88% and 81%
respectively (p ¼ 0.23).
This was a small single centre
trial that found no difference
between policies in terms of
primary assisted patency,
secondary patency or
amputation rates. Notably, no
protocol is available and it was
pseudo-randomised. It is
unclear whether outcomes
were prespecified and there




Studies evaluating occlusion rates
of lower limb arterial bypass with






Mean follow-up was 49 months
in the clinical follow-up group
versus 40 in the DUS
This meta-analysis found lower
rates of graft occlusion and
death in series that reported
(continued on next page)
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Table 1 (continued )
Author, date
and country
Patient group Study type and level of
evidence
Outcomes Key results Comments
studies provided outcomes within
DUS surveillance programs and/or
within clinical surveillance
programs. In total 17 studies (2680
patients) evaluated outcomes with
DUS surveillance. 26 studies (3969
patients) evaluated outcomes with
clinical follow-up only. 43 cohort
studies and one randomised
controlled trial were included.
surveillance group.
583/3677 graftsa in the clinical
group occluded after 30 days
from surgery compared with
165/1332a in the DUS group
(p < 0.01).
357/2842 limbs required
amputation in the clinical group
versus 85/664 in the DUS group
(p > 0.5).
718/3677 patients died during
follow-up in the clinical group
versus 96/843 in the DUS
surveillance group (p < 0.001).
results from DUS surveillance
programs compared to series
that reported outcomes from
clinical follow-up programs.
There was no difference in
amputation rates. As it is mostly
based upon observational data
it is prone to bias. Death and
amputation were infrequently
reported in DUS surveillance
program series. Notably
patency rates were not
evaluated. The principle
message from this review was
that there was strong rationale
for a large randomised
controlled trial.
ABPI e ankleebrachial pressure index; CI e confidence interval; DUS e duplex ultrasound; HR e hazard ratio.
a Data were provided in numbers of grafts rather than number of patients.
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In [patients with infrainguinal arterial bypasses with vein con-
duits] does [routine DUS surveillance in addition to clinical exam-
ination] improve [outcomes].4. Search strategy
We searched Medline up to 19th April 2014 using the following
search strategy [(duplex ultrasound surveillance) AND (vein graft
OR bypass)]. The search was limited to English language studies.
We identified additional studies by examining included article
references. Eligible studies involved patients who underwent
infrainguinal arterial bypasses using vein grafts. Eligible studies
compared follow-up strategies comprising clinical examination
and routine DUS with follow-up strategies comprising clinical ex-
amination and selective imaging. The outcomes of interest were
primary patency, primary assisted patency, secondary patency,
occlusions, amputations and mortality. There was no restriction on
length of follow-up. The definitions for patency outcomes were
those specified by the Society for Vascular Surgery and the North
American Chapter of the International Society for Cardiovascular
Surgery [2]: primary patency is patency without intervention,
primary assisted patency is patency without intervention plus
patency after intervention for graft stenosis, secondary patency is
patency without intervention plus patency after intervention for
graft stenosis plus patency after intervention for graft occlusion.We
excluded studies that involved synthetic conduits unless studies
reported on both vein and synthetic conduits and provided sepa-
rate results for each.5. Search outcome
The search identified 319 Medline citations. 4 studies provided
the best evidence to answer the question.6. Results
3 randomised controlled trials and one meta-analysis were
included. These are summarised in Table 1.7. Discussion
Davies et al. [3] performed a multi-centre randomised
controlled trial involving 594 patients. Eligible patients had un-
dergone femoropopliteal or femorocrural vein bypass and had a
patent graft at 30 days after surgery. Patients were randomised to
“clinical” follow-up, comprising clinical examination and ABPI
measurement at each visit or “DUS” follow-up, comprising clinical
examination, ABPI measurement and additional DUS scanning at
each visit. Follow-up appointments for both groups were are 6
weeks and at 3, 6, 12 and 18 months following surgery. All patients
were offered DUS at study completion (18months). Outcomes were
time to amputation and vascular mortality, patency rates, quality of
life and costs. The groups were well matched at baseline e median
age was 70 in each group and 72% were males; median ABPI at
baseline was 0.48 in the clinical group and 0.49 in the DUS group;
37% in both groups had below knee grafts and 66% of operations in
both groups were for critical ischaemia. There were no significant
differences in terms of outcomes. Therewere 21 amputations in the
clinical group versus 21 in the DUS group (HR 1.01; 95%CI
0.55e1.86). Vascular death occurred in 10 clinical group patients
versus 12 DUS group patients (HR 1.21; 95%CI 0.52e2.81). Corre-
sponding figures for all-cause mortality were 31 in the clinical
group and 36 in the DUS group (HR 1.22; 95%CI 0.75e1.98). Patency
rates and quality of life were also similar although the DUS group
incurredmore cost. This was a high quality triale it had a published
protocol [4] with pre-specified outcome measures, the methodol-
ogy for random sequence generation and allocation concealment
was robust, there were few patients lost to follow-up and all out-
comes were reported. However, the trial achieved just over half of
anticipated recruitment leaving it prone to type 2 error e it was
terminated prematurely due to recruitment difficulties arising from
increased use of percutaneous revascularisation techniques.
Lundell et al. [5] performed a single-centre randomised
controlled trial that evaluated the effects of “routine” versus
“intensive” surveillance programs. Eligible patients underwent
primary femoropopliteal or femorodistal bypass using either vein
or synthetic grafts (results were provided separately for both types
of grafts). “Routine” surveillance comprised clinical examination
and ABPI measurement at 1,12, 24 and 36months after surgery and
“intensive” surveillance comprised clinical examination, ABPI
measurement and DUS scanning at 1, 3, 6, 9, 12, 15, 18, 24 and 36
months following surgery. Outcomes were assisted primary
patency and secondary patency rates. The groups were well
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rately for vein graft patients) e median age was 74 years in the
intensive group versus 76 in routine surveillance group; 49% were
male in the intensive group versus 42% in the routine group; 72/79
intensive group patients had critical ischaemia versus 74/77 routine
group patients. 56 patients in the intensive group and 50 in the
routine group had vein grafts e at 3 years intensive surveillance
lead to significantly better primary assisted patency rates (78% in
intensive group versus 53% in routine group, p < 0.05) and sec-
ondary patency rates (82% in intensive group versus 56% in routine
group, p < 0.05). Importantly, this trial compared “intensive” with
“routine” surveillance rather than routine DUS with selective im-
aging e the increased number of follow-up visits in the DUS group
is amajor source of confounding as it may account for the improved
patency results. A further limitation is that several aspects of
methodological quality are unclear e there is no available protocol,
the methodology for randomisation and allocation concealment is
unclear, it is unclear whether outcomes were prespecified and
there was no justification for the chosen sample size.
Ihlberg et al. performed a single centre randomised controlled
trial that was reported in two different publications [6,7]. The first
related to recruitment from 1991 to 1993, involving 179 patients
[6], and the second related to recruitment from 1991 to 1995,
involving 344 patients [7]. The second publication dealt solely with
patients who attended all follow-up visitse for the purposes of this
review the first publication [6] provided more relevant data
although patient numbers were smaller. Eligible patients under-
went primary infrainguinal bypasses with vein conduits. Once
patency was confirmed at 30 days patients were randomised to
clinical follow-up comprising clinical examination and ABPI mea-
surement or to a follow-up program that additionally involved DUS
scanning at each visit. Follow-up visits for both groups were at 1, 3,
6, 9 and 12 months following surgery. Outcomes were primary
assisted patency, secondary patency and limb salvage rates at one
year. The groups were well matched at baseline e mean age was
69.8 years in the clinical group versus 68.8 in the DUS group, 74%
were male in the clinical group versus 62% in the DUS group; 62/76
clinical group patients had critical ischaemia versus 66/76 in the
DUS group. No significant differences were found in primary
assisted patency (74% in the clinical group and 65% in the DUS
group, p ¼ 0.21) or limb salvage rates (88% and 81% respectively,
p ¼ 0.23) although secondary patency rates were improved (84%
and 71% respectively, p ¼ 0.04). A major limitation is that several
aspects of methodology are unclear or inadequate e no protocol is
available, it was pseudo-randomised based on odd or even dates of
birth, it is unclear whether outcomes were prespecified and there
was no sample size justification.
The final study was a systematic review and meta-analysis by
Golledge et al. [8]. The authors compared pooled data from studies
involving DUS surveillance with pooled data from studies with
clinical follow-up programs. This was achieved through a Medline
search from 1987 to 1995. Eligible studies provided data on oc-
clusion rates. Additional outcomes that were included were am-
putations and deaths during follow-up. 17 studies (2680 patients)
evaluated outcomes within DUS surveillance programs and 26
studies (3969 patients) evaluated outcomes within clinical follow-
up programs. Though not all studies reported all relevant baseline
and outcome data, the groups were similar at baseline e similar
proportions of patients in both groups had critical ischaemia (2842/
3969 (72%) in clinical surveillance versus 1342/1838 (73%) in DUS
surveillance, p ¼ 0.3) and similar ratios of femoropopliteal to crural
surgery (2049:1365 in the clinical group versus 1216:800 in the
DUS group, p > 0.5). However mean follow-up was 49 months in
the clinical follow-up group versus 40 in the DUS surveillancegroup (no p value available). Results suggested that DUS surveil-
lance had a favourable effect on occlusion rates but no effect on
amputations or mortality. The main strength of this review is the
large sample size e at the time of its publication it provided a
strong rationale for the completion of a large randomised control
trial [4]. However as it involved mostly observational data, con-
clusions based upon the review are prone to bias and confounding.
8. Clinical bottom line
Results from available data are conflicting. The strongest evi-
dence comes from the trial by Davies et al. [3] as the smaller trials
and observational studies have major limitations. It appears as
though routine DUS surveillance does not yield benefits in patient
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